The hypoparathyroidism treatment space has made a buzz in 2024 with a major drug approval, acquisitions, and big advances in ...

Expert Rev Endocrinol Metab. 2012;7(3):255-257. The future of hormone replacement therapy in hypoparathyroidism can be viewed with optimism, even if we are left with several unanswered questions ...

Hypoparathyroidism impacts multiple organs and affects an estimated 70,000 to 90,000 people in the U.S. Yorvipath is a prodrug of parathyroid hormone (PTH[1-34]), administered once daily, designed ...

After turning it down a year ago, the FDA has cleared once-daily injectable Yorvipath for hypoparathyroidism from Ascendis Pharma. Yorvipath (palopegteriparatide) – previously known as TransCon ...

Considering taking supplements to treat hypoparathyroidism? Below is a list of common natural remedies used to treat or reduce the symptoms of hypoparathyroidism. Follow the links to read common ...

Analysts initiated coverage on Septerna, Inc. with Overweight ratings and price targets of $50 and $38. SEPN's innovative ...

MBX Biosciences, a recent IPO, develops precision peptide therapies for endocrine and metabolic disorders, with lead asset MBX 2109 in phase 2 for Hypoparathyroidism. MBX 2109, a once-weekly PTH ...

Moreover, the lead product, SEP-786, shows promise as a convenient oral alternative to existing injectable treatments for hypoparathyroidism. The preclinical results have been impressive, showing ...